论文信息 - Immune biomarker-based enrichment in sepsis trials - 字舞流文

Immune biomarker-based enrichment in sepsis trials

C. Meisel | J. Schefold | S. von Gunten | Thibaud Spinetti

[1] S. Gunten. The Future of Pharmacology: Towards More Personalized Pharmacotherapy and Reverse Translational Research. , 2020 .

[2] S. von Gunten. The Future of Pharmacology: Towards More Personalized Pharmacotherapy and Reverse Translational Research , 2019, Pharmacology.

[3] R. Gallop,et al. Plasma sTNFR1 and IL8 for prognostic enrichment in sepsis trials: a prospective cohort study , 2019, Critical Care.

[4] C. Meisel,et al. Assessment of immune organ dysfunction in critical illness: utility of innate immune response markers , 2017, Intensive Care Medicine Experimental.

[5] J. Schefold. Measurement of monocytic HLA-DR (mHLA-DR) expression in patients with severe sepsis and septic shock: assessment of immune organ failure , 2010, Intensive Care Medicine.

[6] N. Voirin,et al. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock , 2006, Intensive Care Medicine.

[7] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..